Marker of Diagnosis and Prognosis in Multiple Sclerosis
OwnerHorea Rus, Cornelia Cudrici +1inventors
InventorsHorea Rus, Cornelia Cudrici, Cosmin Tegla
Life of this patent
Estimating the term…
Abstract
The present invention provides a method for determining whether an individual with relapsing-remitting multiple sclerosis will suffer a relapse. In the method, measuring the level of Response Gene to Complement (RGC)-32 is measured in the individual, where a significantly lower level of RGC-32 therein indicates that the individual will have or is having a relapse of multiple sclerosis.
Claims28
A method for determining whether an individual with relapsing-remitting multiple sclerosis will suffer a relapse, comprising the step of:
- measuring the level of Response Gene to Complement-32 in said individual, wherein a significantly lower level of Response Gene to Complement-32 in said individual indicates that said individual will have or is having a relapse of multiple sclerosis.
A method for determining whether an individual with relapsing-remitting multiple sclerosis will respond positively to a pharmacologic treatment for multiple sclerosis, comprising the step of:
- measuring the level of Response Gene to Complement (RGC)-32 in said individual, wherein the absence of a significant decrease in the level of RGC-32 in said individual indicates that said individual will respond positively or is responding positively to a pharmacologic treatment for multiple sclerosis.
A method for determining whether an individual with relapsing-remitting multiple sclerosis is in a period of stable disease or is not at risk for relapse of multiple sclerosis, comprising the step of:
- measuring the level of Response Gene to Complement-32 in said individual, wherein a significantly higher level of Response Gene to Complement-32 in said individual indicates that said individual is in a period of stable disease or is not at risk for relapse of multiple sclerosis.
Dependencies are inferred from the claim text.